FDA clears 2nd COVID booster for Americans ages 50 and up
The U.S. Food and Drug Administration on Tuesday authorized a second booster dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines for use in adults ages 50 and older, NBC News reports.
Individuals are eligible for a second booster dose at least four months after receiving their first booster, the FDA said, per NBC News. It does not matter which brand of vaccine a person initially received.
Centers for Disease Control and Prevention Director Rochelle Walensky is expected to sign off on the decision shortly. The FDA had already authorized a fourth shot for immunocompromised Americans, per NBC News.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The CDC will likely say people older than 50 can get a second booster, rather than explicitly recommending they do so, The Washington Post reports, "a reflection of the ongoing debate about the benefits of additional doses and uncertainties about the future of the pandemic." The federal agency will also likely "highlight vulnerable populations" within the designated age group.
Even with the FDA and (eventually) CDC's decision, health officials "likely face an uphill battle in another vaccine campaign," notes The Wall Street Journal. Approximately two-thirds of adults over age 65 have received a booster, and less than half of the adult population has.
The extra shots will be available through "physician offices, retail pharmacies, nursing homes and other vaccination sites," per the Journal. A fourth shot is expected to be authorized for the broader population this fall.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brigid Kennedy worked at The Week from 2021 to 2023 as a staff writer, junior editor and then story editor, with an interest in U.S. politics, the economy and the music industry.
-
Covid four years on: have we got over the pandemic?
Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
By Chas Newkey-Burden, The Week UK Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
Excess screen time is making children only see what is in front of them
Under the radar The future is looking blurry. And very nearsighted.
By Devika Rao, The Week US Published
-
Covid-19: what to know about UK's new Juno and Pirola variants
in depth Rapidly spreading new JN.1 strain is 'yet another reminder that the pandemic is far from over'
By Arion McNicoll, The Week UK Published
-
Long-term respiratory illness is here to stay
The Explainer Covid is not the only disease with a long version
By Devika Rao, The Week US Published
-
Seattle Children's Hospital sues Texas over 'sham' demand for transgender medical records
Speed Read Texas Attorney General Ken Paxton subpoenaed records of any Texan who received gender-affirming care at the Washington hospital
By Peter Weber, The Week US Published
-
Afghanistan has a growing female suicide problem
Speed Read The Taliban has steadily whittled away women's and girls' rights in Afghanistan over the past 2 years, prompting a surge in depression and suicide
By Peter Weber, The Week US Published